CTSO Earnings

Quarterly EPS
$-1.00
Q3 2024
$-3.01
Q4 2024
$-0.40
Q1 2025
$0.60
Q2 2025
$-1.00
Q3 2025
$-1.75
Q4 2025
$-1.60
Q1 2026
$-1.40
Q2 2026
Latest Revenue9.6M
Latest Net Income-4417000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$1.409.6M-4417000+0.2%-333.3%
Q1 2026-$1.608.9M-5129000+1.6%-300.0%
Q4 2025-$1.759.2M-5497000+0.9%+41.9%
Q3 2025-$1.009.5M-3170000+10.1%+0.0%
Q2 2025$0.609.6M1.9M+8.8%+137.5%
Q1 2025-$0.408.7M-1479000-2.9%+81.8%
Q4 2024-$3.019.2M-7567000+168.8%-6.7%
Q3 2024-$1.008.6M-2768000-2.2%+76.2%
Q2 2024-$1.608.8M-4294000——
Q1 2024-$2.209.0M-6088711——
Q4 2023-$2.823.4M-6574273——
Q3 2023-$4.208.8M-9193520——
Cytosorbents (CTSO) — Earnings